 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In a report released on April 5, Justine Telliez from Kepler Capital maintained a Buy rating on Genfit (GNFTF Research Report), with a price targ...

Kepler Capital  Keeps Their Buy Rating on Genfit (GNFTF)

Genfit (GNFT) has released an update. GENFIT, a biopharmaceutical company focusing on liver diseases, reported a solid financial position with 77...

GENFIT Announces Strong 2023 Financials and Progress

Genfit S.A. (NASDAQ:GNFT - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 98,900 shares, an...

Genfit S.A. (NASDAQ:GNFT) Sees Large Increase in Short Interest

Genfit (NASDAQ:GNFT  Get Free Report) and Neurocrine Biosciences (NASDAQ:NBIX  Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two...

Genfit (NASDAQ:GNFT) versus Neurocrine Biosciences (NASDAQ:NBIX) Head-To-Head Survey

This price move could indicate a change in the trend, and may be a sell signal for investors...

Genfit SA (GNFT, $3.89) price exceeded its 50-day Moving Average on February 14, 2024

This indicator may be signaling that GNFT's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Genfit SA (GNFT, $3.89) entered Downtrend as Momentum indicator drops below 0 level on Feb 13, 2024

This price move may be construed as a buy signal, as it indicates the trend is shifting higher...

Genfit SA (GNFT, $3.89) 50-day Moving Average moved above its 200-day Moving Average on February 13, 2024

Genfit SA (GNFT, $3.56) price exceeded its 50-day Moving Average on February 07, 2024

This is a Bearish indicator signaling GNFT's price could decline from here. Traders may explore shorting the stock or put options...

Genfit SA (GNFT, $3.83) Moving Average Convergence Divergence (MACD) Histogram turned negative on February 6, 2024

Genfit SA (GNFT, $3.83) entered Downtrend as Momentum indicator drops below 0 level on Feb 06, 2024

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.

Volume (M)	2,067.00
52-Wk High	$4.75
52-Wk Low	$2.89

GNFT Genfit

About

Feed

News

Earnings

Fundamentals